Eli Lily

Demand for the blockbuster anti-obesity drugs, which help control blood sugar and slow digestion, has been on an upswing

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand

The U.S.-based Lilly beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India

Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial

In the 751-person trial, Zepbound helped patients lose an average of 20.2% of their weight after 72 weeks compared to 13.7% for the group treated with Wegovy, Lilly said

World Street | US jobs data, Eli Lilly's revised forecast, bumper profits for European insurers and more

From China's higher-than-expected spike in consumer prices to Deliveroo, Eli Lilly and Under Armour's strong quarterly numbers and growth forecasts, here's a look at some of the major developments from across the world.

Lily's Cymbalta patent expiry, little cheer for generic cos

Latest patent expiration of Eli Lily‘s anti-depressant drug Cymbalta, which had annual US sales of USD 5.5 billion, has not materialised as anticipated by the Indian generic drug makers, reports CNBC TV18‘s Archana Shukla.

Indian pharma cos welcome 'outsiders' to up global presence

Last few months saw some high profile changes in the managements of Indian pharma companies. Entirely promoter-controlled companies giving way to professional managements brought in from top multinationals to drive global ambitions, reports CNBC-TV18's Archana Shukla.

Orchid, Aurobindo get nod to sell Schizophrenia drug copy

Orchid Chemicals and Pharmaceuticals and rival Aurobindo Pharma have received US Food and Drug Administration (FDA) approval for their abbreviated new drug application (ANDA) for Olanzapine tablets, a generic version of Eli Lilly's Zyprexa tablets, in various strengths.

Novo Nordisk bets on blockbuster drug to retain top spot

Multi-national drug companies are queuing up to enter India and tap its growing anti-diabetes drug market. But Novo Nordisk, which has been in the Indian insulin market for 75 years, is not worried, reports CNBC-TV18's Archana Shukla.